Fenwick & West represented Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene therapies for various forms of limb-girdle muscular dystrophies (LGMDs), with respect to the intellectual property and licensing aspects of its transaction with Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Under this transaction, Sarepta will make an upfront payment of $60 million and additional development-related milestone payments to purchase an exclusive option to acquire Myonexus at a pre-negotiated, fixed price with sales-related contingent payments. More information about this transaction can be obtained from Myonexus Therapeutics’ press release.

Stefano Quintini assisted Myonexus with support from technology transaction partner Jake Handy.

Login

Don’t have an account yet?

Register